Drugs / BRV-PV
BRV-PV
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02584816 | Nov 2015 → Apr 2017 | Rotavirus infection | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02145000 | Jun 2014 → Dec 2015 | Rotavirus infection | Epicentre | Completed | No outcome recorded |
| Phase 3 | NCT02133690 | May 2014 → Mar 2016 | Rotavirus infection | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRV-PV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02145000 ↗ |
| Known as | Bovine Rotavirus Pentavalent Vaccine | “Bovine Rotavirus Pentavalent Vaccine (BRV-PV)” NCT02584816 ↗ |
| Known as | bovine-human reassortant pentavalent rotavirus vaccine | “A bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) targeting the globally most common strains was developed in India and tested in a randomized, double-blind,...” PMID 28967523 ↗ Sep 2017 |
| Known as | Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine | “Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in...” NCT02133690 ↗ |
| Known as | ROTASIIL | “We assessed the extended and strain-specific vaccine efficacy of a heat-stable, affordable oral rotavirus vaccine (Rotasiil, Serum Institute of India, Pune, India) against...” PMID 34214095 ↗ Jul 20211“A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL®) was tested for its potential effect on the immunogenicity of concomitantly administered EPI...” PMID 30104114 ↗ Aug 2018 |
| Modality | Vaccine | “bovine-human reassortant pentavalent rotavirus vaccine” PMID 28967523 ↗ Sep 2017 |
| Route | Oral | “BRV-PV administered orally” NCT02133690 ↗ |